MRTNZ

MRTNZ Investment Office · S&P 500 · The 360 Vantage

ABT · NYSE

Abbott Laboratories

Health Care · Biotechnology: Pharmaceutical Preparations

Reference price$107.27As of Jul 28, 2026
Market capitalization$187B
52-week range$81.97–$137.49
S&P 500 portfolio weight0.29%
Data qualitycomplete

Street view

Analyst targets

Published sell-side aggregation—not an MRTNZ forecast.

Low$112.00+4.4% vs. reference
Average$120.15+12.0% vs. reference
High$135.00+25.9% vs. reference
14 Buy0 Hold0 Sell

Forward calendar

Current earnings expectations

Consensus may change until the company reports.

Expected reportNot availableSep 2026
Consensus EPS$1.428 estimates
Expected range$1.41–$1.45Low to high EPS
Dec 2026$5.52Street EPS consensus
Dec 2027$6.08Street EPS consensus
Dec 2028$6.74Street EPS consensus

Reported results

Annual financial snapshot

Fiscal period ended Dec 31, 2025.

MetricCurrentPrior
Revenue+5.7% YoY$44.33B$41.95B
Operating income$8.05B$6.83B
Net income$6.52B$13.4B
Operating cash flow$9.57B$8.56B
Capital expenditures($2.17B)($2.21B)

Current context

Related news

Company-linked articles surfaced by Nasdaq.

Zacks

These 3 Companies Reported Record Results and Raised Guidance

Zacks

Abbott Rides Key Diabetes, Oncology and Heart Care Innovation Trends

BNK Invest

SCHD, CUSD: Big ETF Inflows

Evidence

Sources & method

Nasdaq quote →Nasdaq summary →Earnings forecast →Annual financials →Official S&P 500-tracking holdings →

Facts, estimates, and scenarios are kept separate. Analyst targets and EPS expectations are third-party estimates, not MRTNZ forecasts. Index weight uses the official IVV portfolio as the denominator. Illustrative research, not investment advice.